In vitro polymyxin activity against clinical multidrug-resistant fungi.
Candida albicans
MDR-fungi
Molds
Polymyxin antibiotics
Repurposing-drug
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
12
2018
accepted:
10
04
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
28
5
2020
Statut:
epublish
Résumé
Although antifungals are available and usually used against fungal infections, multidrug-resistant (MDR) fungal pathogens are a growing problem for public health. Moreover, fungal infections have become more prevalent nowadays due to the increasing number of people living with immunodeficiency. Thus, previously rarely-isolated and/or unidentified fungal species including MDR yeast and moulds have emerged around the world. Recent works indicate that polymyxin antibiotics (polymyxin B and colistin) have potential antifungal proprieties. Therefore, investigating the in vitro activity of these molecules against clinical multidrug-resistant yeast and moulds could be very useful. In this study, a total of 11 MDR yeast and filamentous fungal strains commonly reported in clinical settings were tested against polymyxin antibiotics. These include strains belonging to the Polymyxin B and colistin exhibited an antifungal activity against all MDR fungal strains tested with MICs ranging from 16 to 128 μg/ml, except for the colistin could be proposed, in clinical practice, in association with other antifungals, to treat life-threatening fungal infections caused by MDR yeasts or moulds.
Sections du résumé
Background
Although antifungals are available and usually used against fungal infections, multidrug-resistant (MDR) fungal pathogens are a growing problem for public health. Moreover, fungal infections have become more prevalent nowadays due to the increasing number of people living with immunodeficiency. Thus, previously rarely-isolated and/or unidentified fungal species including MDR yeast and moulds have emerged around the world. Recent works indicate that polymyxin antibiotics (polymyxin B and colistin) have potential antifungal proprieties. Therefore, investigating the in vitro activity of these molecules against clinical multidrug-resistant yeast and moulds could be very useful.
Methods
In this study, a total of 11 MDR yeast and filamentous fungal strains commonly reported in clinical settings were tested against polymyxin antibiotics. These include strains belonging to the
Results
Polymyxin B and colistin exhibited an antifungal activity against all MDR fungal strains tested with MICs ranging from 16 to 128 μg/ml, except for the
Conclusion
colistin could be proposed, in clinical practice, in association with other antifungals, to treat life-threatening fungal infections caused by MDR yeasts or moulds.
Identifiants
pubmed: 31044071
doi: 10.1186/s13756-019-0521-7
pii: 521
pmc: PMC6480676
doi:
Substances chimiques
Antifungal Agents
0
Polymyxins
0
Polymyxin B
J2VZ07J96K
Colistin
Z67X93HJG1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Déclaration de conflit d'intérêts
Not applicable.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Mycoses. 2016 Nov;59(11):678-690
pubmed: 27061755
J Med Microbiol. 1970 Aug;3(3):529-38
pubmed: 4319621
Int J Antimicrob Agents. 2017 Jun;49(6):740-748
pubmed: 28433743
Clin Microbiol Rev. 2008 Jul;21(3):449-65
pubmed: 18625681
Indian J Ophthalmol. 2016 May;64(5):346-57
pubmed: 27380973
J Antimicrob Chemother. 2010 May;65(5):931-8
pubmed: 20167587
J Cyst Fibros. 2009 May;8(3):211-7
pubmed: 19372063
Antimicrob Agents Chemother. 2014 Oct;58(10):5795-800
pubmed: 25049251
Int J Antimicrob Agents. 2018 Jan;51(1):10-15
pubmed: 28669833
Antimicrob Agents Chemother. 1998 Jul;42(7):1587-91
pubmed: 9660988
Int J Antimicrob Agents. 2018 Jul;52(1):11-13
pubmed: 29580929
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6998-6999
pubmed: 27620480
Afr J Infect Dis. 2010;4(1):1-6
pubmed: 23878695
Antimicrob Agents Chemother. 2010 Jan;54(1):484-90
pubmed: 19858263
Transplant Proc. 2019 Jan - Feb;51(1):202-205
pubmed: 30661895
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27821445
J Antimicrob Chemother. 2013 Jun;68(6):1285-96
pubmed: 23378416
Intern Med J. 2007 Jul;37(7):495-8
pubmed: 17547727
Mycoses. 2013 May;56(3):297-303
pubmed: 23170818
Ann N Y Acad Sci. 2019 Jan;1435(1):57-78
pubmed: 29762860
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2234-9
pubmed: 22308411
Microb Drug Resist. 2019 Jan/Feb;25(1):63-71
pubmed: 30129868
Lancet Infect Dis. 2016 Feb;16(2):147
pubmed: 26711360
BMJ Case Rep. 2016 Aug 03;2016:
pubmed: 27489066
Br J Haematol. 2014 Aug;166(4):471-84
pubmed: 24749533
Int J Antimicrob Agents. 2017 Nov;50(5):599-606
pubmed: 28669835
Clin Infect Dis. 2008 Jan 1;46(1):120-8
pubmed: 18171227
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27503996
J Fungi (Basel). 2017 Aug 26;3(3):
pubmed: 29371563
Eukaryot Cell. 2007 Nov;6(11):1933-42
pubmed: 17873085
FEMS Yeast Res. 2014 Nov;14(7):1068-79
pubmed: 25154541
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
Int J Antimicrob Agents. 2017 Nov;50(5):617-621
pubmed: 28802855
Clin Infect Dis. 2005 Sep 1;41(5):634-53
pubmed: 16080086
J Clin Microbiol. 2007 Jun;45(6):1811-20
pubmed: 17428932
Br J Ophthalmol. 2004 Jan;88(1):25-8
pubmed: 14693766
Clin Infect Dis. 2001 Aug 15;33(4):550-5
pubmed: 11462194
Am J Med. 2012 Jan;125(1 Suppl):S3-13
pubmed: 22196207
Ann Intensive Care. 2016 Dec;6(1):26
pubmed: 27033711